A prospective, multicenter, observational cohort study assessing the efficacy and safety of radiotherapy-sensitized immunotherapy in advanced breast cancer.
Men or women who are 18 years of age or older on the day of signing the informed consent;
Patients with advanced breast cancer that is inoperable or has metastasized, confirmed by histology or cytology;
Patients who, after MDT discussion at the metastatic breast cancer stage, are considered suitable for radiotherapy and have completed radiotherapy;
Patients who have previously received and continue to use immunotherapy, or are planned to receive immunotherapy, and are scheduled to receive a systemic treatment regimen including immunotherapy as chosen by the physician within 3 weeks after completing radiotherapy;
Subjects with brain metastases or leptomeningeal metastases; if there are any suspected symptoms or signs of CNS involvement, they should be excluded by a cranial MRI scan;
Have not signed the informed consent form;
Pregnant or lactating women;
Other conditions deemed unsuitable for inclusion in the study by the investigator.